GB THERAPEUTICS
GB Therapeutics Changes its Name to Cita NeuroPharmaceuticals
GB Therapeutics Changes its Name to Cita NeuroPharmaceuticals Inc.
MISSISSAUGA, Canada, April 14/PRNewswire/ --
Anthony Giovinazzo, President & CEO of GB Therapeutics Ltd. (GBt),
announced today that the company has changed its name from GB
Therapeutics Ltd. to Cita NeuroPharmaceuticals Inc.
Project names have been changed from:
GT 1512 to CMP 1512
GT 3381 to CMP 3381
GT 1061 to CMP 1061
About Cita NeuroPharmaceuticals
Cita is a neuropharmaceutical company focussed on the development
and commercialization of late stage small molecule drug candidates for
neurological diseases and disorders. The Company leverages its
clinical expertise, business acumen and strategic partnerships to
identify, acquire, develop and market novel drugs. Cita's current
portfolio consists of drugs for Parkinson's disease (CNP1512 entering
Phase 3), neuropathic pain (CNP3381 entering Phase 2) and Alzheimer's
disease (CNP1061 in preclinical development).
Source: GB Therapeutics Ltd. and Cita NeuroPharmaceuticals Inc.
For further information: Anthony Giovinazzo, President & CEO, GB
Therapeutics Ltd., 2480 Dunwin Drive, Mississauga, Ontario, L5L 1J9,
CANADA, Tel: +1-905-607-4903 ext 222, Fax: +1-905-607-7351, Email:
agiovinazzo@gbtherapeutics.comuroPharmaceuticals Inc.
14 apr 05 09:11